Blade Q4 revenue up 24.5% to $47.5M; guides for 2024 Adj. EBITDA profitability

Strata Critical Medical, Inc.

Q4 revenue $47.5M (+24.5% YoY); full year revenue $225.2M (+54.1%).
Net loss widened to $(33.9)M in Q4 from $(15.4)M; Adj. EBITDA improved to $(5.2)M from $(8.0)M.
Full year 2023 Adj. EBITDA $(16.6)M; guides for 2024 Adj. EBITDA profitability and 2025 double-digit millions.
Announced pending purchase of eight jet aircraft to support Medical growth; new organ placement service launched.
Medical segment Adj. EBITDA positive $2.5M in Q4, up 57.8% YoY; Passenger Adj. EBITDA loss improved to $(2.6)M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Strata Critical Medical, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $47,478, net income $(33,941). Guidance initiated.

Period: the fourth quarter ended December 31, 2023
Revenue: $47,478
Net income: $(33,941)
Guidance: initiated
Result: reported results

Exact text from the filing

2023. GAAP FINANCIAL RESULTS (in thousands except percentages, unaudited) Three Months Ended December 31, Year Ended December 31, 2023 2022 % Change 2023 2022 % Change Revenue $ 47,478 $ 38,135 24.5 % $ 225,180 $ 146,120 54.1 % Cost of revenue 38,468 33,160 16.0 % 183,058 123,845 47.8 % Software development 988 1,622 (39.1) % 4,627 5,545 (16.6) % General and

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Strata Critical Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001779128-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.